[Federal Register Volume 68, Number 64 (Thursday, April 3, 2003)]
[Notices]
[Pages 16287-16292]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-8062]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 03034]


Public Health Laboratory Biomonitoring Implementation Program; 
Notice of Availability of Funds

    Application Deadline: July 2, 2003.

A. Authority and Catalog of Federal Domestic Assistance Number

    This program is authorized under sections 301 and 317 of the Public 
Health Service Act, 42 U.S.C. 241 and 247b, as amended. The catalog of 
Federal Domestic Assistance number is 93.283.

B. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 2003 funds for cooperative agreements 
to establish or expand state public health laboratory biomonitoring 
capacity. This program addresses the ``Healthy People 2010'' focus 
areas of Environmental Health and Public Health Infrastructure. This 
program builds upon biomonitoring planning conducted by State public 
health laboratories during FY 2001 and FY 2002 under Program 
Announcement (PA) 01072, Public Health Laboratory Biomonitoring 
Planning Grant. PA 01072 can be viewed at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2001_register&docid=01-11215-filed.
    The purpose of this program is to implement and expand State 
laboratory-based biomonitoring programs to assess human exposure to 
environmental toxicants, help prevent disease resulting from exposure 
to toxic substances, and determine estimates of background exposure to 
naturally occurring and industrial chemicals that have the potential to 
cause harm.
    Measurable outcomes of the program will be in alignment with one or 
more of the following performance goals for the National Center for 
Environmental Health (NCEH):
    1. Develop laboratory capacity to monitor human exposures to 
environmental chemicals.
    2. Periodically determine the number of Americans exposed to 
environmental chemicals and the degree of their exposure.
    3. Increase the capacity of State and local health departments to 
deliver environmental health services in their communities.

C. Eligible Applicants

    Assistance will be provided only to public health laboratories of 
States or lead States of consortia that were recipients of CDC grants 
for biomonitoring planning in FY2001 and FY2002 under PA 01072 (see 
Attachment 3 as posted on the CDC Web site for a listing of funded 
grantees under PA 01072). No other applications are solicited.
    Applications are only sought from those grantees under PA 01072, 
who have developed a biomonitoring plan and the necessary relationships 
and contacts to implement their plan. These grantees have spent two 
years on the development of their biomonitoring plans. New applicants 
would not have those plans in place, and therefore would not be ready 
to move into the implementation phase being funded by this new 
announcement.
    States, territories, or protectorates that do not meet the 
preceding requirement may participate by entering into a consortium or 
other agreement with an eligible State or an eligible consortium of 
States.
    Only one application per State or consortium may be submitted. A 
State may apply as an individual State or as the lead member of a 
consortium, but not both. Members of a consortium may not apply as 
individual States.

    Note: Title 2 of the United States Code section 1611 states that 
an organization described in section 501c(4) of the Internal Revenue 
Code that engages in lobbying activities is not eligible to receive 
Federal funds constituting an award, grant or loan.


[[Page 16288]]



D. Funding

Availability of Funds

    Approximately $5,000,000 is available in FY 2003 to fund 
approximately ten awards. Funding will range from $200,000, up to 
$3,000,000 per award. Funding estimates may change. It is expected that 
the awards will begin on or about September 15, 2003, and will be made 
for an initial 9-month budget period, which will end on June 30, 2004. 
Future budget periods will be 12 months in duration for a total project 
period of up to four years and nine months.
    Continuation awards within an approved project period will be made 
on the basis of the availability of funds and satisfactory progress as 
evidenced by required reports.
    Funding will be awarded in two categories:
    Individual States: Maximum award of up to $1,000,000 for individual 
States.
    Consortia: Maximum award of up to $3,000,000 based upon the number 
of States within the consortium. A range of $200,000-$600,000 per State 
consortium member is anticipated.
    Applications exceeding the foregoing maxima will be returned 
without review. Eligible applicants are only allowed to apply for one 
of the two categories described above.

Use of Funds

    Funds may be used to develop and implement a biomonitoring program, 
conduct demonstration projects, purchase equipment and supplies, hire 
and train personnel, conduct appropriate and relevant travel, hire 
consultants, pay for services, and renovate or modify existing 
laboratory areas. Funds provided by CDC under this cooperative 
agreement may not be used for construction of new laboratory space. 
Funds may not be used to support activities otherwise funded, or 
eligible to be funded, through the Superfund Program or the Agency for 
Toxic Substances and Disease Registry. However, because toxicants from 
Superfund sites may contribute to the total exposures of a given 
population, funds may be used to assess the exposure status of 
populations not already addressed under Superfund.

Funding Preferences

    Preference for awards will be given to ensure geographic diversity, 
distribution, and balance among laboratories which serve people living 
in various settings such as urban, rural, agricultural, and industrial 
communities; among laboratories that have various levels of expertise, 
experience, capacity, and need for biomonitoring. Preference will be 
given to applications with the greatest need for biomonitoring 
expansion or implementation based on documented or suspected 
environmental toxicant exposures among persons living within the 
applicant's area of responsibility.

Recipient Financial Participation

    Matching funds are not required for this program.

E. Program Requirements

    In conducting activities to achieve the purpose of this program, 
the recipient will be responsible for the activities listed under 1. 
Recipient Activities, and CDC will be responsible for the activities 
listed under 2. CDC Activities.
    1. Recipient Activities:
    a. Implement and apply biomonitoring laboratory capacity by 
following, as closely as possible, the biomonitoring plan(s) that the 
recipient developed with funding under PA 01072, Public Health 
Laboratory Biomonitoring Planning Grant.
    b.Address the needs for, and proposed application of, biomonitoring 
within the community served by the applicant and distinguish between 
those needs that are single issue and those that exist on an on-going 
basis. Collaborate with other public health partners, including public 
health physicians and epidemiologists, in making this needs assessment. 
Special consideration should be given to evaluating exposures in under-
served population groups that may be at increased risk from exposure. 
(E.g. minorities, the very young, and the elderly may have a greater 
risk of exposure or harmful effects.)
    c. Incorporate the application of laboratory data to respond to 
important public health issues as listed in items 1. through 6. of 
Attachment 2, ``Biomonitoring and Complementary Programs.'' Please see 
all attachments referenced in this announcement as posted with the full 
announcement on the CDC Web site: http://www.cdc.gov/od/pgo/funding/grantmain.htm. Uses may include population based or targeted health 
exposure surveys, health effects studies, sentinel monitoring of at-
risk populations, case-control studies, studies involving analyses of 
stored specimens, or other recognized epidemiologic tools. The 
applicant must develop complete study protocols after award of a 
cooperative agreement and prior to commencing the study.
    d. Meet requirements for local Institutional Review Board (IRB) or 
Human Subjects review and obtain approval for any such projects which 
constitute research as defined in 45 CFR part 46. (See http://ohrp.osophs.dhhs.gov/humansubjects/guidance/45cfr46.htm#46.102)
    e. Biomonitoring research projects that the applicant plans to 
undertake without substantial CDC involvement do not require CDC IRB 
approval. However, the applicant will be required to submit a copy of 
their proposed protocol and a copy of their IRB approval letter (and 
all subsequent approval renewals) to CDC. Research projects that 
applicants wish to undertake with substantial CDC involvement will 
require joint development of detailed protocols with CDC and approval 
from both CDC IRB and the applicant's local IRB. Note: CDC IRB may 
defer to the local IRB or the local IRB may defer to CDC IRB. Because 
funds currently available to support the biomonitoring implementation 
program under this cooperative agreement are limited and are primarily 
intended for biomonitoring capacity building, applicants are 
discouraged from relying on this agreement to fund complex and costly 
epidemiologic studies. Rather, activities should be limited to 
demonstration projects, pilot surveys, and preliminary investigations. 
More detailed and costly epidemiologic studies employing biomonitoring 
should be developed jointly and in detail among the interested 
laboratories, their epidemiology partners, and others with funding 
sought from other sources as stand-alone projects.
    f. Implement the plan for developing (or expanding) and applying 
biomonitoring capacity in the public health laboratory. This 
implementation must follow the specific, measurable, and time-framed 
goals and objectives presented in the plan.
    g. Develop an evaluation plan by which the recipient may conduct 
periodic and on-going assessments of progress in expanding the 
laboratory's biomonitoring capacity and to assess the impact of 
biomonitoring measurements on addressing the identified public health 
needs within the state(s) or community.
    h. Participate in external proficiency testing and quality control 
programs, perform biomonitoring pilot and demonstration studies 
(including performance of biomonitoring analyses on previously 
collected samples), participate in the prospective planning and conduct 
of biomonitoring research projects or population exposure surveys, and 
perform other activities that enhance the recipient's ability to 
implement a biomonitoring program.
    2. CDC Activities:

[[Page 16289]]

    a. Provide technical assistance, guidance, and training in 
biomonitoring, including information about analytical methods and 
instrumentation used by CDC for biomonitoring.
    b. Provide information about sources for reagents, supplies, 
standards, quality assurance materials, equipment, etc. These sources 
may include commercial vendors, other Federal, State, or international 
agencies, professional societies or standard-setting bodies, 
contractors to CDC, and CDC laboratories, as appropriate.
    c. Provide analytical support as requested for biomonitoring 
studies initiated by the recipient (subject to availability and 
competing national priorities).
    d. Assist in the development of a research protocol for projects in 
which CDC provides a staff member to serve as principal investigator or 
co-investigator or when CDC conducts sample analysis. IRB approval will 
be required from all institutions participating in the research. CDC 
IRB must review and approve the protocol initially and at least on an 
annual basis until the research project is completed. For those 
research projects that do not have a CDC staff member serving as the 
principal investigator or co-investigator, technical assistance in the 
form of advice, recommendations, and expert opinions will be provided.

F. Content

Letter of Intent (LOI)

    A LOI is optional for this program. The Program Announcement title 
and number must appear in the LOI. The narrative should be no more than 
one page, single-spaced, printed on one side, with one-inch margins, 
and unreduced 12-point font. The LOI will be used for CDC planning 
purposes. The LOI must indicate whether the applicant plans to apply as 
an individual state applicant or as the lead member of a consortium and 
should identify the states that are anticipated to be consortium 
partners.

Applications

    The Program Announcement title and number must appear in the 
application. Use the information in the Program Requirements, Content, 
Other Requirements, and Evaluation Criteria sections to develop the 
application content. The application will be evaluated on the criteria 
listed, so it is important to follow them in laying out the program 
plan. The narrative should be no more than 25 pages, double-spaced, 
printed on one side, with one-inch margins, and unreduced 12-point 
font.
    The narrative should consist of, at a minimum, a Workplan, 
Objectives, Methods, Personnel, Evaluation Scheme, and Budget. A two- 
to three-page executive summary of the applicant's plan developed under 
PA 01072 shall be included preceding the narrative. The application 
must also include, as an attachment, a full copy of the plan from the 
planning grant. The page limitation is exclusive of the attached copy 
of the plan.
    The application must also:
    1. Discuss how the recipient will develop, implement, and apply 
biomonitoring laboratory capacity by following the biomonitoring plan 
that was developed with funding under PA 01072.
    2. Outline how biomonitoring will be applied within the community 
served by the applicant and distinguish between those needs that are 
single issue and those that exist on an on-going basis. Describe how 
collaboration with other public health partners, including public 
health physicians and epidemiologists in making this needs assessment 
will be accomplished. Special consideration should be given to 
evaluating exposures in under-served population groups that may be at 
increased risk from exposure.
    3. Discuss how the program will use biomonitoring laboratory data 
to answer the important public health questions as listed in items 1. 
through 6. of Attachment 2 as posted on the CDC Web site. The 
application should not include complete study protocols, as they will 
be developed after award of a cooperative agreement and prior to 
commencing the study.
    4. Tell how requirements for local IRB or Human Subjects review 
will be met and how approval for any such projects which constitute 
research as defined in 45 CFR part 46 will be obtained. (See http://ohrp.osophs.dhhs.gov/humansubjects/guidance/45cfr46.htm#46.102.)
    5. Provide an inventory of existing biomonitoring methods in use by 
the applicant, and for each method specify: Toxic substance(s) 
measured; method of measurement (e.g., GC-MS, atomic absorption); 
current instrumentation used; the limit of detection for each analyte 
(and how the limit of detection was determined); known interferences; 
description of method's quality control; any external proficiency 
testing program in which the laboratory currently participates for the 
method; an approximate sample throughput per day; and the approximate 
number of human specimens analyzed in the past 12 months. Emphasize in 
this section how the existing biomonitoring capacity will be used to 
address needs identified in the paragraphs above. As part of this 
explanation, specify the collaborations with public health partners 
(State and local health officials, schools of public health, academic 
centers, community groups, etc.) who will work with the laboratory to 
use biomonitoring data to help address these public health needs. 
Include documentation from each public health partner of its 
willingness to collaborate. Acceptable documentation may be letters of 
support or formal agreements among partners.
    6. For each new biomonitoring method needed, describe additional 
requirements for personnel, instrumentation, and facilities 
modification or expansion. Provide cost estimates for facilities 
modification or expansion, if applicable.
    7. Describe specimen management and security protocols that are in 
place or that are to be implemented to support the biomonitoring 
program.
    8. Describe the data management and communications resources and 
plans available or needed to support the biomonitoring program. The 
relationship (or lack thereof) with other public health data management 
and communications initiatives (e.g., National Electronic Disease 
Surveillance System, Health Alert Network, etc.) should be discussed.
    9. Discuss requirements for compliance with the Clinical Laboratory 
Amendments of 1988 (CLIA).
    10. Develop an evaluation plan to provide periodic and on-going 
assessment of progress in expanding the laboratory's biomonitoring 
capacity and to assess the impact of biomonitoring measurements on 
addressing the identified public health needs within the State(s) or 
community.
    11. Applications from consortia must provide documentation from 
each member of the consortium of their willingness to collaborate, to 
share resources, and/or to perform work within the consortium under 
reciprocal arrangements, to pool data from each site in their proposed 
consortium as appropriate to the goals of the consortium, and to 
participate in periodic meetings (or conferences via electronic media) 
among consortium laboratories for the purpose of planning, conduct of 
consortium business, training, and technology transfer. Acceptable 
documentation may be letters of support or formal agreements among the 
consortium members.
    12. Discuss anticipated problems with the implementation of the 
biomonitoring plan and outline proposed solutions. Potential problems 
might include state restrictions on

[[Page 16290]]

hiring of personnel, travel restrictions, and shortages of qualified 
personnel.

G. Submission and Deadline

Letter of Intent (LOI) Submission

    On or before May 5, 2003, submit the LOI to the Grants Management 
Specialist identified in the ``Where to Obtain Additional Information'' 
section of this announcement.

Application Forms

    Submit the signed original and two copies of PHS Form 5161--
    1. Forms are available at the following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
    If you do not have access to the Internet, or if you have 
difficulty accessing the forms on-line, you may contact the CDC 
Procurement and Grants Office Technical Information Management Section 
(PGO-TIM) at: 770-488-2700. Application forms can be mailed to you.

Submission Date, Time, and Address

    The application must be received by 4 p.m. eastern time on July 2, 
2003. Submit the application to: Technical Information Management--
PA03034, Procurement and Grants Office, Centers for Disease Control and 
Prevention, 2920 Brandywine Rd, Atlanta, GA 30341-4146. Applications 
may not be submitted electronically.

CDC Acknowledgement of Application Receipt

    A postcard will be mailed by PGO-TIM, notifying you that CDC has 
received your application.

Deadline

    Letters of intent and applications shall be considered as meeting 
the deadline if they are received before 4 p.m. eastern time on the 
deadline date. Any applicant who sends their application by the United 
States Postal Service or commercial delivery services must ensure that 
the carrier will be able to guarantee delivery of the application by 
the closing date and time. If an application is received up to two 
weeks after the closing date, due to (1) carrier error, when the 
carrier accepted the package with a guarantee for delivery by the 
closing date and time, or (2) significant weather delays or natural 
disasters, CDC will upon receipt of proper documentation, consider the 
application as having been received by the deadline.
    Any application that does not meet the above criteria will not be 
eligible for competition, and will be discarded. The applicant will be 
notified of their failure to meet the submission requirements.

H. Evaluation Criteria

Application

    Applicants are required to provide measures of effectiveness that 
will demonstrate the accomplishment of the various identified 
objectives of the cooperative agreement. Measures of effectiveness must 
relate to the performance goals as stated in section ``A. Purpose'' of 
this announcement. Measures must be objective and quantitative and must 
measure the intended outcome. These measures of effectiveness shall be 
submitted with the application and shall be an element of evaluation.
    An independent review group appointed by CDC will evaluate each 
application against the following criteria:
1. Understanding the Requirements for Implementing a Biomonitoring Plan 
(30 Percent)
    Does the application reflect the biomonitoring plan developed by 
the applicant and is a copy of the biomonitoring plan included as an 
attachment? (Note: If the application is from a consortium that 
includes members previously funded as individual planning grantees, the 
application must reflect the planning of those consortium members and 
discuss how those plans will be integrated.) The extent to which the 
applicant describes the need for a biomonitoring program, and an 
understanding of the purpose of conducting exposure assessment by 
measurement of human biological samples (blood, hair, urine, saliva) to 
identify internal human dose from contact with hazardous environmental 
chemicals. The applicant's understanding of the analytical challenges 
associated with identifying the extent of exposure based on data 
obtained from human samples, especially challenges presented by the 
differences in physiological makeup of individuals, specimen 
collection, and pharmacokinetic and pharmacodynamic factors. The 
demonstration of understanding the problems related to estimating or 
extrapolating ``internal dose'' from ``external dose'' data, and the 
value of biomonitoring through direct measurement of samples from 
humans to provide information that is more meaningful.
2. Goals and Objectives (20 Percent)
    The extent to which the applicant clearly states biomonitoring 
program goals and objectives which are consistent with the Purpose and 
Program Requirements sections as presented in this announcement, and 
the degree to which the goals and objectives reflect an understanding 
of the need to reach beyond the laboratory to achieve balanced input 
from the broader public health community in implementation of the 
biomonitoring plan. These goals and objectives shall include a 
discussion of the implementation of biomonitoring laboratory capacity 
and application of this capacity to specific environmental chemical 
exposure problems.
3. Program and Methodology (20 Percent)
    Describe in detail how the biomonitoring laboratory plan will be 
implemented. This must include a description of space allocation, 
staffing requirements and training, instrumentation and instrumentation 
maintenance, analytical methods, specimen storage and security, supply 
accession, facilities, quality assurance and quality control, 
logistical support and data management. The applicant shall provide a 
phased timeline of activities leading to implementation or expansion of 
a biomonitoring program by the applicant. Does this description of 
activities fully cover the anticipated four-year, nine-month project 
period? Does the application adequately address the CDC Policy 
requirements regarding the inclusion of women, ethnic, and racial 
groups in the proposed research? This includes:
    a. The proposed plan for the inclusion of both sexes and under-
served populations for appropriate representation.
    b. The proposed justification when representation is limited or 
absent.
    c. A statement as to whether the design of the study is adequate to 
measure differences when warranted.
    d. A statement as to whether the plans for recruitment and outreach 
for study participants include the process of establishing partnerships 
with community(ies) and recognition of mutual benefits.
4. Collaborative Efforts (15 Percent)
    Describe anticipated collaborative efforts related to this program 
among the applicant laboratory(ies), other components of the public 
health structure of the community, including epidemiologists, 
environmental health professionals, other state or local health 
agencies, health services providers, and academic institutions such as 
schools of public health, medicine, university departments of chemistry 
or biochemistry, community and citizens groups, and other interested 
parties. Letters of support from anticipated collaborators must be 
provided as

[[Page 16291]]

attachments to the application package. The page limitation is 
exclusive of the attached letters of support. The applicant must 
discuss how collaborators propose to employ biomonitoring to address 
public health issues/concerns. The applicant shall discuss 
complementary and competing programs if applicable, such as 
environmental testing programs, terrorism preparedness programs, 
environmental public health tracking programs, and other activities 
that may add to or detract from biomonitoring capacity.
5. Evaluation Plan (10 Percent)
    The extent to which the applicant describes how progress towards 
achieving the applicant's goals and objectives will be evaluated, and 
how, during the implementation phase, new public health needs will be 
assessed and the program (and the underlying plan) will be modified to 
adjust to these changing public health needs and priorities. The 
application's approach to evaluating the impact of the program on 
environmental health and human exposure issues in the applicant's 
community will also be evaluated.
6. Staffing, Management System, and Facilities (5 Percent)
    The extent to which the applicant describes the staff that is 
available or anticipated to conduct these activities and how they will 
be managed and evaluated. The applicant must describe the 
organizational setting and facilities available to support the 
biomonitoring program; to access, transport, store, inventory, process 
and manage biological specimens from people; and to accumulate, 
process, store, and analyze data and other information related to the 
implementation of this program. Applicants must also describe planning 
to provide IRB review when biomonitoring programs are implemented, and 
discuss the impact of the requirements of CLIA on their plan.
7. Budget (Not Scored)
    The extent to which the applicant provides a detailed budget and 
narrative justification consistent with stated objectives and program 
activities.
    You are encouraged to use Out-of-State travel funds to send one 
staff person to attend the sixth National Environmental Health 
Conference to be held on December 3-5, 2003, at the Hilton Atlanta, 255 
Courtland Street, NE., Atlanta, GA. If additional written justification 
is needed to support attendance at the above meeting, please contact 
your project officer. Review the CDC/NCEH Web site for additional 
information concerning the conference: http://www.cdc.gov/nceh/default.htm.
8. Human Subjects (Not Scored)
    Does the application adequately address the requirements of title 
45 CFR part 46 for the protection of human subjects? Not scored; 
however, an application can be disapproved if the research risks are 
sufficiently serious and protection against risks is so inadequate as 
to make the entire application unacceptable.

I. Other Requirements

OMB Clearance Requirements

    Projects that involve the collection of information from 10 or more 
individuals and funded by the cooperative agreement will be subject to 
review and approval by the Office of Management and Budget (OMB) under 
the Paperwork Reduction Act.

Technical Reporting Requirements

    Provide CDC with original plus two copies of:
    1. Interim progress report, no less than 90 days before the end of 
the budget period. The progress report will serve as a non-competing 
continuation application, and must contain the following elements:
    a. Current Budget Period Activities Objectives.
    b. Current Budget Period Financial Progress.
    c. New Budget Period Program Proposed Activity Objectives.
    d. Detailed Line-Item Budget and Justification.
    e. Additional Requested Information.
    2. Financial status report, no more than 90 days after the end of 
the budget period.
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    Send all reports to the Grants Management Specialist identified in 
the ``Where to Obtain Additional Information'' section of this 
announcement.

Additional Requirements

    The following additional requirements are applicable to this 
program. For a complete description of each, see Attachment 1 of the 
program announcement as posted on the CDC Web site.

AR-1 Human Subjects Requirements
AR-2 Requirements for Inclusion of Women and Racial and Ethnic 
Minorities in Research
AR-7 Executive Order 12372 Review
AR-9 Paperwork Reduction Act Requirements
AR-10 Smoke-Free Workplace Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-22 Research Integrity

J. Where To Obtain Additional Information

    This and other CDC announcements, the necessary applications, and 
associated forms can be found on the CDC Web site, Internet address: 
http://www.cdc.gov.
    Click on ``Funding'' then ``Grants and Cooperative Agreements''.
    For interested applicants, a telephone conference call for pre-
application technical assistance will be held on April 21, 2003, at 1 
p.m. eastern time. Potential applicants are requested to call in using 
only one telephone line. The conference can be accessed by calling 1-
800-311-3437 or 404-639-3277 and entering conference code 824087 when 
prompted. The purpose of the conference call is to help potential 
applicants to:
    1. Understand the scope and intent of the Program Announcement for 
the Public Health Laboratory Biomonitoring Implementation Program.
    2. Be familiar with the Public Health Services funding policies and 
application and review procedures.
    Participation in this conference call is not mandatory. At the time 
of the call, if problems are encountered accessing the conference call, 
please call 404-639-7550. For further information, please contact 
Charles Buxton at (770) 488-4160 or Barry E. Smith at (770) 488-7968.
For general questions about this announcement, contact: Technical 
Information Management, CDC Procurement and Grants Office, 2920 
Brandywine Rd, Atlanta, GA 30341-4146. Telephone: 770-488-2700.
For business management and budget assistance, contact: Mildred S. 
Garner, Grants Management Officer, Procurement and Grants Office, 
Centers for Disease Control and Prevention, 2920 Brandywine Road, (MS 
E-13), Atlanta, GA 30341-4146. Telephone: (770) 488-2745. E-mail 
address: [email protected].
For program technical assistance, contact: Charles H. Buxton, 
MT(ASCP)SBB, National Center for Environmental Health, Centers for 
Disease Control and Prevention, 4770 Buford Highway, NE. (MS F-20), 
Atlanta, GA 30341-3724. Telephone: (770) 488-4160. E-mail address: 
[email protected].
 Or:
Barry E. Smith, National Center for Environmental Health, Centers for 
Disease Control and Prevention, 4770 Buford Highway, NE. (MS F-20),

[[Page 16292]]

 Atlanta, GA 30341-3724. Telephone: (770) 488-7968. E-mail address: 
[email protected].

    Dated: March 27, 2003.
Sandra R. Manning,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 03-8062 Filed 4-2-03; 8:45 am]
BILLING CODE 4163-18-P